Business Context and Reporting Period
Company: Broadstone Net Lease, Inc. (BNL)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: BNL is an industrial-focused, diversified net lease REIT investing in single-tenant commercial real estate. As of December 31, 2024, the portfolio consisted of 765 properties (758 in the U.S., 7 in Canada) totaling approximately 39.4 million rentable square feet. The portfolio is 99.1% leased with a weighted average remaining lease term of 10.2 years.
Key Financial Metrics
| Metric | 2024 Value | Per Share (Diluted) |
|---|---|---|
| Net Income | $169.0 million | $0.86 |
| Funds From Operations (FFO) | $300.7 million | $1.52 |
| Core FFO | $295.5 million | $1.50 |
| Adjusted FFO (AFFO) | $282.0 million | $1.43 |
| Total Debt Outstanding | $1.9 billion | - |
| Net Debt | $1.9 billion | - |
| Leverage Ratio (Net Debt/Adj. EBITDAre) | 5.0x | - |
| Annualized Base Rent (ABR) | $395.5 million | - |
Material Changes vs. Prior Period
- Portfolio Strategy Shift: Substantially completed the clinical healthcare simplification strategy by selling 58 properties for gross proceeds of $364.0 million. Core property types were updated to industrial, retail, and other.
- Investment Activity: Invested $404.8 million in 2024, including $234.3 million in new acquisitions, $115.3 million in build-to-suit developments, and $52.2 million in transitional capital.
- Revenue: Net lease revenues decreased by 2.5% to $431.8 million, primarily due to a decrease in lease termination fee income and realizable revenues from clinical healthcare properties, partially offset by redeployment into revenue-generating properties.
- Impairments: Recognized $49.0 million in impairment charges, primarily related to the strategic decision to sell clinically-oriented healthcare properties.
- Gains on Sale: Recognized a gain of $73.2 million on the sale of real estate, compared to $54.3 million in 2023.
- Interest Expense: Decreased by 7.5% to $74.1 million, driven by capitalized interest on developments and lower variable-rate revolver balances.
Guidance, Outlook, and Risks
Outlook and Commentary: Management expects to achieve growth through embedded same-store NOI growth, revenue-generating capital expenditures, build-to-suit developments, and a diversified acquisition pipeline. The company aims to maintain a leverage ratio generally below 6.0x. All proceeds from healthcare sales have been redeployed into core verticals.
Risks and Contingencies:
- Tenant Concentration: Top 10 tenants represent 21.9% of ABR; no single tenant exceeds 4.1%.
- Interest Rate Risk: Exposure to variable-rate debt, though 97.2% of debt is fixed via rates or swaps.
- REIT Status: Failure to qualify as a REIT would result in significant tax consequences.
- Environmental & Legal: Potential liabilities related to environmental conditions and standard litigation risks.
Investor Verification Checklist
- Healthcare Portfolio Transition: Verify the timeline and financial impact of the remaining clinical healthcare asset sales and the accretion of redeployed capital.
- Debt Maturities: Review the debt maturity schedule, noting the $93.0 million revolver and $400.0 million term loan maturing in 2026.
- Forward Sale Agreements: Confirm the settlement terms and estimated proceeds ($38.5 million) of the unsettled forward sale agreements under the ATM program.
- Impairment Methodology: Assess the valuation assumptions used for the $49.0 million impairment charge to ensure fair value estimates are robust.
- Tenant Credit Quality: Monitor the financial health of the top 10 tenants, which collectively account for nearly 22% of rental income.